Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-cash Items (2016 - 2023)

Editas Medicine (EDIT) has disclosed Non-cash Items for 9 consecutive years, with $2.6 million as the latest value for Q2 2023.

  • Quarterly Non-cash Items rose 39.31% to $2.6 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Jun 2023, up 39.31% year-over-year, with the annual reading at $401.5 million for FY2022, 92.05% down from the prior year.
  • Non-cash Items for Q2 2023 was $2.6 million at Editas Medicine, down from $236.5 million in the prior quarter.
  • The five-year high for Non-cash Items was $5.1 billion in Q4 2021, with the low at $1.3 million in Q2 2021.
  • Average Non-cash Items over 5 years is $636.4 million, with a median of $12.8 million recorded in 2019.
  • The sharpest move saw Non-cash Items plummeted 96.7% in 2019, then surged 116301.4% in 2022.
  • Over 5 years, Non-cash Items stood at $26.1 million in 2019, then skyrocketed by 543.28% to $167.6 million in 2020, then surged by 2913.88% to $5.1 billion in 2021, then tumbled by 92.05% to $401.5 million in 2022, then tumbled by 99.36% to $2.6 million in 2023.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $2.6 million, $236.5 million, and $401.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.